Patent ID: 7144909

Claim:
A compound of the general formula: or pharmaceutically acceptable salts, stereoisomers, prodrug ester forms or radioactive forms thereof, wherein; R 1 is selected from: carboxylic acid (—CO 2 H), phosphonic acid (—PO(OH) 2 ), phosphamic acid (—PO(OH)NH 2 ), sulphonic acid (—SO 2 OH), and hydroxamic acid (—CONHOH) groups; Z is selected from: —(CH 2 ) n —, and —(CH 2 ) m CH(R a )—; R 2 and R 3 are independently selected from: halogen, C 1-4 alkyl, and C 1-4 alkyl substituted with 1, 2 or 3 R b groups which may be the same or different; R 4 is selected from: C 6-10 aryl, C 5-9 heteroaryl, C 1-4 alkyl, and C 1-4 alkyl substituted with 1, 2, or 3 R c groups which may be the same or different, said aryl and heteroaryl being optionally substituted with 1, 2, or 3 R d groups which may be the same or different; X is selected from: —O—, —S—, and —N(R e )—; Y is selected from: —CH—, and —N—; R a is selected from: —OH, —NH 2 , —NH(C 1-4 alkyl), —NH(C 2-4 alkenyl), and —NH(C 2-4 alkynyl), or a bioisosteric equivalent; R c is selected from: hydrogen, C 6-10 aryl, C 5-9 heteroaryl, C 6-10 aryloxy, C 5-9 heteroaryloxy, N(C 6-10 aryl) 2 , —NH(C 6-10 aryl), —N(C 5-9 heteroaryl) 2 , —NH(C 6-9 heteroaryl), —N(C 1-4 alkyl)(C 6-10 aryl), —N(C 1-4 alkyl)(C 6-9 heteroaryl), and —N(C 6-10 aryl)(C 5-9 heteroaryl) or a bioisosteric equivalent; R d is selected from: hydrogen, fluorine, —OH, C 1-2 alkoxy, N(C 1-4 alkyl) 2 , and —NH(C 1-4 alkyl) or a bioisosteric equivalent; R e is selected from: hydrogen, and C 1-2 alkyl; n is 1, 2 or 3; m 1 or 2.